Imugene Ltd has released a press release.
Appendix 4E and Audited Financial Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Imugene
- PD-1 cancer vaccine development update
- Imugene raises $20.1 million
- Imugene Licences Extensive B-Cell Immuno-Oncology Portfolio
- Leslie Chong Appointed as Managing Director
- Arginine Modulator Active in Cancer Models
Later from Imugene
- Imugene Completes Phase 1b Cancer Vaccine Trial Recruitment
- Imugene commences cGMP manufacture of PD-1 cancer vaccine
- Imugene Receives $1.85 million R&D Tax Incentive
- Imugene Advances to Phase 2 in Gastric Cancer Trial
- IMU Meets Endpoints in Phase 1b Gastric Cancer Trial
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene